Stevens-Johnson syndrome after treatment with STI571: A case report

Liang Tsai Hsiao; Hung Ming Chung; Jen Tsun Lin; Tzeon Jye Chiou; Jin Hwang Liu; Frank S. Fan; Wei Shu Wang; Chueh Chuan Yen; Po Min Chen

doi:10.1046/j.1365-2141.2002.03499.x

Stevens-Johnson syndrome after treatment with STI571: A case report

Liang Tsai Hsiao, Hung Ming Chung, Jen Tsun Lin, Tzeon Jye Chiou, Jin Hwang Liu, Frank S. Fan, Wei Shu Wang, Chueh Chuan Yen, Po Min Chen

Research output: Contribution to journal › Article › peer-review

110 Citations (Scopus)

Abstract

Between seven and 21% of patients treated with the specific tyrosine kinase inhibitor STI571 have been reported to develop mild-to-moderate severity of adverse cutaneous reactions. We report a patient in the blast crisis phase of chronic myeloid leukaemia who developed a life- threatening cutaneous reaction, Stevens-Johnson syndrome, following 1 week of STI571 therapy. This report may serve to remind the clinician about the possible severe cutaneous side-effects of STI571 before instituting more extensive clinical application of this agent in the future.

Original language	English
Pages (from-to)	620-622
Number of pages	3
Journal	British Journal of Haematology
Volume	117
Issue number	3
DOIs	https://doi.org/10.1046/j.1365-2141.2002.03499.x
Publication status	Published - 2002
Externally published	Yes

Keywords

Chronic myeloid leukaemia
Skin
Stevens-Johnson syndrome
STI571
Tyrosine kinase inhibitor

ASJC Scopus subject areas

Hematology

Access to Document

10.1046/j.1365-2141.2002.03499.x

Cite this

@article{a829ace4020a41ec922225fb02ca613d,

title = "Stevens-Johnson syndrome after treatment with STI571: A case report",

abstract = "Between seven and 21% of patients treated with the specific tyrosine kinase inhibitor STI571 have been reported to develop mild-to-moderate severity of adverse cutaneous reactions. We report a patient in the blast crisis phase of chronic myeloid leukaemia who developed a life- threatening cutaneous reaction, Stevens-Johnson syndrome, following 1 week of STI571 therapy. This report may serve to remind the clinician about the possible severe cutaneous side-effects of STI571 before instituting more extensive clinical application of this agent in the future.",

keywords = "Chronic myeloid leukaemia, Skin, Stevens-Johnson syndrome, STI571, Tyrosine kinase inhibitor",

author = "Hsiao, {Liang Tsai} and Chung, {Hung Ming} and Lin, {Jen Tsun} and Chiou, {Tzeon Jye} and Liu, {Jin Hwang} and Fan, {Frank S.} and Wang, {Wei Shu} and Yen, {Chueh Chuan} and Chen, {Po Min}",

year = "2002",

doi = "10.1046/j.1365-2141.2002.03499.x",

language = "English",

volume = "117",

pages = "620--622",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Stevens-Johnson syndrome after treatment with STI571

T2 - A case report

AU - Hsiao, Liang Tsai

AU - Chung, Hung Ming

AU - Lin, Jen Tsun

AU - Chiou, Tzeon Jye

AU - Liu, Jin Hwang

AU - Fan, Frank S.

AU - Wang, Wei Shu

AU - Yen, Chueh Chuan

AU - Chen, Po Min

PY - 2002

Y1 - 2002

N2 - Between seven and 21% of patients treated with the specific tyrosine kinase inhibitor STI571 have been reported to develop mild-to-moderate severity of adverse cutaneous reactions. We report a patient in the blast crisis phase of chronic myeloid leukaemia who developed a life- threatening cutaneous reaction, Stevens-Johnson syndrome, following 1 week of STI571 therapy. This report may serve to remind the clinician about the possible severe cutaneous side-effects of STI571 before instituting more extensive clinical application of this agent in the future.

AB - Between seven and 21% of patients treated with the specific tyrosine kinase inhibitor STI571 have been reported to develop mild-to-moderate severity of adverse cutaneous reactions. We report a patient in the blast crisis phase of chronic myeloid leukaemia who developed a life- threatening cutaneous reaction, Stevens-Johnson syndrome, following 1 week of STI571 therapy. This report may serve to remind the clinician about the possible severe cutaneous side-effects of STI571 before instituting more extensive clinical application of this agent in the future.

KW - Chronic myeloid leukaemia

KW - Skin

KW - Stevens-Johnson syndrome

KW - STI571

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=0036110317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036110317&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2002.03499.x

DO - 10.1046/j.1365-2141.2002.03499.x

M3 - Article

C2 - 12028031

AN - SCOPUS:0036110317

SN - 0007-1048

VL - 117

SP - 620

EP - 622

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 3

ER -

Stevens-Johnson syndrome after treatment with STI571: A case report

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this